Given the improvement in hepatic steatosis after PPARα activation, we hypothesized the B2D+ fenofibrate treatment caused inversion of the alignments between B2D and NAFLD transcription networks. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.